Stockreport

Syndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference

Syndax Pharmaceuticals, Inc.  (SNDX) 
Last syndax pharmaceuticals, inc. earnings: 3/3 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.syndax.com
PDF – Launched Revuforj® (revumenib) for treatment of R/R acute leukemia with a KMT2A translocation in adult and pediatric patients one year and older –– Revumenib added to [Read more]